TXA-127 is under clinical development by Constant Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect TXA-127’s likelihood of approval (LoA) and phase transition for Cardiomyopathy took place on 01 Dec 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their TXA-127 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

TXA-127 overview

TXA-127 is under development for the treatment of marfan syndrome, diabetes, amyotrophic lateral sclerosis (ALS), dystrophic epidermolysis bullosa (DEB), laminin-deficient congenital muscular dystrophy (LAMA), Limb-girdle muscular dystrophy (LGMD) and coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome causing coronavirus 2 (SARS-CoV-2). It is administered through oral, parenteral subcutaneous and intravenous route. It is a naturally occurring peptide Angiotensin (1-7). It is developed based on the Peptelligence platform that comprises peptide oral drug delivery for the enhanced delivery of TXA-127. It was also under development for chemotherapy induced thrombocytopenia, HIV, double cord stem cell engraftment, pulmonary arterial hypertension, ischemic stroke, peripheral vascular disease, myelodysplastic syndrome, hematopoietic stem cell transplantation and Duchenne muscular dystrophy (DMD).

Constant Therapeutics overview

Constant Therapeutics is a biopharmaceutical company that develops drugs that target the alternative renin-angiotensin system, the protective arm of the renin-angiotensin system, and also develops Mas receptor agonists for the treatment of COVID-19, CNS, and rare disorders. Constant Therapeutics is headquartered in Boston, Massachusetts, the US.

Quick View TXA-127 LOA Data

Report Segments
  • Innovator
Drug Name
  • TXA-127
Administration Pathway
  • Intravenous
  • Oral
  • Parenteral
  • Subcutaneous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Dermatology
  • Genetic Disorders
  • Hematological Disorders
  • Immunology
  • Infectious Disease
  • Metabolic Disorders
  • Musculoskeletal Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.